Evotec SE (EVO) Q1 2026 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call reveals a mixed performance with negative revenue growth and gross margin challenges, countered by optimistic guidance and strategic partnerships. Liquidity remains stable, and management expresses confidence in achieving guidance, but lacks specificity in quarterly forecasts. The market cap suggests moderate sensitivity to news, leading to a neutral prediction for stock price movement over the next two weeks.

Key Financial Performance

Group Revenues EUR 156.6 million, a decrease of EUR 43.4 million or 21.7% year-over-year. The decline was due to continuous market softness for early clinical discovery, the nonrecurrence of a $25 million license sale to Sandoz in the prior year, and negative foreign exchange effects.

Adjusted Group EBITDA Negative EUR 21.9 million, compared to EUR 3.1 million in the prior year period. The decline was primarily driven by the nonrepeat of the Sandoz license payment and challenging market conditions.

D&PD Revenues EUR 119.9 million, a decrease of EUR 20.7 million or 14.7% year-over-year. The decline was due to challenging market conditions and FX headwinds.

Just-Evotec Biologics Revenue EUR 36.8 million, a decrease of EUR 22.6 million or 38% year-over-year. The decline was primarily driven by the nonrecurrence of the $25 million Sandoz license sale and the expected decline in DoW revenues, partially offset by year-over-year growth of non-DoW/non-Sandoz revenues by approximately 50%.

R&D Expenses EUR 10.1 million, representing 6.4% of total revenue, compared to EUR 14.9 million or 7.5% of total revenue in the prior year. The decrease reflects tightly focused spending on projects most relevant to partners.

Liquidity EUR 444.8 million, a decrease of EUR 31.6 million compared to the end of the fourth quarter 2025. The decline reflects improved operating cash flow, disciplined capital expenditure, and excludes expected gross proceeds of approximately $100 million from the Gilead acquisition of Tubulis.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

AI-enabled discovery and translational platforms: Evotec's AI-enabled platforms have been instrumental in advancing tuberculosis drug discovery and translational research, supported by grants from the Gates Foundation. These platforms also enabled faster preclinical candidate development in collaboration with Almirall.

Global health initiatives: Evotec received two new grants from the Gates Foundation to accelerate tuberculosis drug discovery and translational research.

Public sector engagement: Collaborations with BARDA on Ebola and Sudan viruses preparedness highlight Evotec's role in public health.

Horizon business transformation: Evotec initiated the Horizon plan to streamline operations, improve cost discipline, and align resources with strategic priorities. This includes site consolidation in the U.S. and personnel adjustments in Europe.

Leadership enhancements: Appointments of Ashiq Khan as Chief Commercial Officer, Ingrid Muller as Chief Operating Officer, and Claire Hinshelwood as Chief Financial Officer to strengthen operational and financial leadership.

Strategic evaluation: Evotec is conducting a strategic evaluation of its portfolio, capital structure, and ownership framework to optimize value creation.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Market Environment: Continued softness in the early drug discovery market and challenging market conditions impacting demand for discovery and preclinical development (D&PD) services.

Revenue Decline: Significant year-on-year revenue decline of 21.7% in Q1 2026, driven by nonrecurrence of a $25 million license sale, foreign exchange headwinds, and market softness.

Foreign Exchange Headwinds: Negative foreign exchange effects, particularly from the U.S. dollar and British pound, contributed to a revenue decline of EUR 10.2 million in Q1 2026.

Operational Restructuring: Implementation of the Horizon initiative involves significant restructuring, including site closures (e.g., Framingham site in the U.S.), personnel adjustments, and reorganization costs of EUR 75 million, which may disrupt operations in the short term.

Profitability Challenges: Adjusted group EBITDA for Q1 2026 was negative EUR 21.9 million, reflecting lower revenues and ongoing restructuring costs.

Liquidity Concerns: Quarterly liquidity decreased by EUR 31.6 million to EUR 444.8 million, though expected proceeds from a portfolio sale may provide relief in Q2 2026.

Execution Risks: The Horizon initiative's success depends on effective implementation of cost-saving measures and operational adjustments, with potential risks of delays or inefficiencies.

Customer Confidence: While there are early signs of stabilization, customer confidence and investments remain fragile, as evidenced by ongoing softness in D&PD demand.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Full Year 2026 Revenue Guidance: Evotec confirms its full-year 2026 revenue guidance of EUR 700 million to EUR 789 million, or EUR 730 million to EUR 810 million at constant exchange rates.

Full Year 2026 Adjusted EBITDA Guidance: The company expects adjusted EBITDA to range between EUR 0 million to EUR 40 million, or EUR 10 million to EUR 15 million at constant exchange rates.

Second Half 2026 Performance Expectations: Revenue and profitability are expected to improve over the course of the year, with performance weighted towards the second half of 2026.

Market and DPD Recovery: Improvement in revenue and profitability is anticipated to be driven by market recovery and increasing visibility across the strategic partnership pipeline.

Horizon Initiative Savings: Structural run rate savings of approximately EUR 75 million are expected by the end of 2027, with 20% to 30% of these savings materializing in 2026.

Commercial Momentum in D&PD: Positive signals include stabilization in delivery metrics, increased proposal activity, and a 15% year-on-year increase in net sales orders in Q1 2026.

Strategic Evaluation: The company is conducting a strategic evaluation of its portfolio, capital structure, and ownership framework to optimize value creation. No predefined outcome or timeline has been set.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:How confident are you in achieving the required ramp-up in quarterly revenues to meet full-year guidance?

A:The management is confident in achieving the ramp-up due to the dynamics of strategic partnerships and milestones. They highlighted that the revenue is not linear and pointed to the expected recovery in the D&PD environment and strategic partnerships in the second half of the year.

Q:Do you need to fully implement Horizon before conducting the strategic review of the group?

A:No, the management stated that they are not required to wait for Horizon's full implementation. Horizon is focused on upgrading the operating model, reducing complexity, and making the company more agile.

Q:What factors contributed to the negative gross margin of -1% in Q1, and what needs to be done to improve it?

A:The negative gross margin was attributed to FX effects, the Sandoz deal, and under-absorption at some sites due to Horizon implementation. As Horizon progresses, the under-absorption will reduce, positively impacting the margin.

Q:What is your visibility on the D&PD market improvement and strategic relationships?

A:The management noted fewer cancellations and better sales order performance over the last three quarters as indicators of market recovery. Strategic relationships are progressing, but their execution timing is uncertain. Quarterly revenue swings are not indicative of full-year results.

Q:Can you provide insights into the underlying profitability and gross margin at Just?

A:The management explained that the volatility in Just's quarterly revenues and margins is due to the phasing of costs and investments versus revenue recognition from milestones and licenses. Q1 results are not conclusive for underlying profitability.

Q:What are your expectations for H2 performance and the impact of strategic partnerships and milestones?

A:The management expects slight underlying growth in the D&PD business and contributions from strategic partnerships and milestones in H2. They confirmed guidance for the full year, indicating growth in the second half.

Q:Is there a seasonal pattern in net sales order progression?

A:The management noted some seasonality, with Q4 typically being strong, but emphasized that milestone events have a bigger impact on revenue than seasonality.

Q:Will you provide more details on the impact of AI-first companies on your long-term growth?

A:The management stated that AI is integrated into their drug discovery capabilities and is not a standalone service. They mentioned that their Cyprotex business has benefited from AI-related demand but did not provide specific numbers.

Q:Was Q1 the trough in operating performance, and what triggered the strategic review?

A:The management did not confirm Q1 as the trough, emphasizing full-year guidance instead. The strategic review was not triggered by inbound interest but is a logical step following the company's reset and Horizon implementation.

Q:How weighted will Q4 be to EBITDA, and what can we expect in Q2?

A:The management did not provide quarterly guidance but highlighted the dynamic difference between H1 and H2, with strategic partnerships and milestones contributing to H2 growth. They emphasized the volatility in quarterly results.

Q:What needs to happen for preclinical spending to recover?

A:The management believes it is a timing issue, with biotech funding stabilizing and cancellations declining. They see AI as a supportive tool rather than a disruptive challenge.

Q:Review of Unclear Management Responses

A:Management avoided providing specific quarterly guidance, particularly for Q2 and Q4, despite repeated questions. They also did not disclose specific numbers for the order book or the impact of AI-first companies on long-term growth.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

EVO Transcript

Evotec SE (EVO) Q1 2026 Earnings Call Transcript

Unknown5-6

Evotec SE (EVO) Q4 2025 Earnings Call Transcript

Unknown4-8

The earnings report shows mixed signals: strong growth in Just-Evotec Biologics and EBITDA, but a decline in overall segment revenues and R&D spending. The Q&A reveals optimism for non-Sandoz revenues and AI adoption, but concerns about BMS revenue decline and lack of clarity on clinical plans. The market cap suggests moderate reactions to these mixed signals, resulting in a neutral stock price prediction.

Evotec SE (EVO) Q3 2025 Earnings Call Transcript

Unknown11-5

The earnings call summary reveals several negative aspects: a 7% decline in group revenues, negative EBITDA, and economic uncertainties. The Q&A highlights concerns about market recovery, profitability, and management's unclear responses. Despite some positive aspects like JEB growth and strategic transactions, the overall sentiment remains negative due to the revenue decline and financial challenges. The market cap indicates a small-cap company, which typically reacts more strongly to negative news, supporting a prediction of a negative stock price movement (-2% to -8%) over the next two weeks.

Evotec SE (EVO) Q2 2025 Earnings Call Transcript

Unknown8-13

The earnings call presents a mixed picture. Strong partnerships and technology leadership are positive, but management's reluctance to provide specifics in the Q&A raises concerns. While strategic partnerships and AI integration are promising, the lack of concrete guidance and details, particularly regarding the Sandoz deal and revenue specifics, may temper enthusiasm. Additionally, the market cap suggests moderate sensitivity to these factors. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.

EVO Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.